Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Malpass, M. Nagel, V. Avvakoumova, R. Ali, H. Schneider, J. Mitchell (London, Canada). Comparative in vitro performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 2: Portable battery-compressor. Eur Respir J 2012; 40: Suppl. 56, 2148

Member's Comments

No comment yet.

Related content which might interest you: Comparative in vitro performance of a new re-usable breath-actuated nebulizer (BAN) with other high performance systems intended for domiciliary use – 1: Table-top compressors Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Adherence and tolerance of an auto-CPAP (APAP) device specially designed for occidental way of life and bedroom: Beyond technology, medical appearance is obsolete Source: Annual Congress 2012 - Advanced experience with long-term noninvasive ventilation and late-breaking abstracts Year: 2012 Highly effective delivery of medication is possible in home use with improved breath-actuated nebulizer (BAN) driven by home compressor Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Optimization of inhalation treatment – Evaluation of influence of spacer integrated with the spirometer on aerosol particle distribution from pMDI-EB Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Valved holding chambers (VHCs) can have different medication delivery performance as a function of delay interval following actuation of the pressurized metered dose inhaler (pMDI) Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Effective and efficient nebulization of alpha1-proteinase inhibitor (alpha1-PI) for inhalation therapy using the AKITA2® APIXNEBÔ nebulizer system Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Delivery of medication by breath-actuated nebulizer (BAN) is similar when used with differing inhalation / exhalation ratios: A contrast to breath enhanced nebulizer (BEN) behavior Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 In vitro characterisation of a novel electronic nebulizer utilising a customised single dose bfs-vial to improve handling and delivery performance Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Accuracy of three activity monitors in patients with COPD – Validation by video Source: Annual Congress 2011 - Physical activity monitors: from toy to valid tool? Year: 2011 Laboratory assessment of drug delivery of Beclomethasone/Formoterol metered dose inhaler (MDI) with a new valved holding chamber (VHC) designed specifically for 'on-the-go' use. Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Evaluation of the technique of use of inhaler devices by patients at home through a video mobile application: A pilot study Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 A breath-actuated jet nebulizer (BAN) has dosimetric capability for a suspension formulation based on differing volume fill of medication as well as run time Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Optimization of inhalation treatment – Assessment of the influence of diluent and air humidity on particle distribution of colistin administered by BCTS method [bronchial control treatment system] Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Combining inhalation by a breath-actuated nebulizer (BAN) with exhalation with oscillating positive expiratory pressure device (OPEP) offers potential for simultaneous therapy Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler® Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 In vitro performance of the prodose AAD® handheld - a new portable aerosol delivery system Source: Eur Respir J 2004; 24: Suppl. 48, 581s Year: 2004 Early experience with home transcutaneous CO2 monitoring (TcCO2/SpO2) in the setting of a domiciliary assisted ventilation service Source: Annual Congress 2010 - From the acute to the chronic patient: how do we use noninvasive ventilation? Year: 2010